ArticleApplied microbiology and biotechnology2025
A chemiluminescence immunoassay for detecting neutralizing antibodies of foot-and-mouth disease virus serotype A.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Foot-and-mouth disease (FMD) is a highly contagious viral disease affecting cloven-hoofed animals, posing significant threats to global livestock industries. Post-vaccination neutralizing antibody levels reflect vaccine efficacy, but traditional virus neutralization tests (VNT) for detecting neutralizing antibodies requires restrictive biocontainment facilities to handle live virus, is time-consuming and laborious. In this study, we successfully established a high-efficiency magnetic particle-based chemiluminescence immunoassay (MP-CLIA) using two previously characterized monoclonal antibodies (W125 and W145) generated through single B cell antibody technology. The MP-CLIA method exhibited a sensitivity of 95.93% and specificity of 100%, with a cut-off value of 41.395 activity units (U) by detecting the known 221 positive and 122 negative sera. The positive/negative coincidence rate between the MP-CLIA and VNT was 92.2% and the kappa coefficient was 78.19%, indicating a relatively high level of consistency. When integrated with a fully automated chemiluminescence immunoassay analyzer, this method only takes 20 min for a single test. These results show that MP-CLIA is a promising tool for the safe, rapid, and fully automatic detection of neutralizing antibodies against FMD virus (FMDV) serotype A. KEY POINTS: A MP-CLIA using two bovine single B cell antibodies was established. The MP-CLIA method exhibited a sensitivity of 95.93% and specificity of 100%. The MP-CLIA specifically detects neutralizing antibodies against FMDV serotype A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.